<DOC>
	<DOCNO>NCT02964507</DOCNO>
	<brief_summary>This combination Phase I Phase II study , aim evaluate combination GSK525762 fulvestrant woman advance metastatic ER+ breast cancer , disease progress prior treatment least one line endocrine therapy . The objective study first identify , open-label single-arm Phase I , recommend Phase II dose GSK525762 may combine safely fulvestrant . Phase I follow modify toxicity probability interval ( mTPI ) design , sentinel group evaluate first dose-limiting toxicity expand collect additional safety data . This follow double-blind , randomize control Phase II , identify clinical activity two study treatment give combination . The composition Phase II select end Phase I . Approximately , 140 subject 154 subject receive study treatment Phase I Phase II respectively . A complete subject one follow death .</brief_summary>
	<brief_title>Dose Escalation Expansion Study GSK525762 Combination With Fulvestrant Subjects With Estrogen Receptor Positive ( ER+ ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Females 18 year old great histologically cytologically confirm diagnosis advance metastatic adenocarcinoma breast . History prior therapy satisfy one follow criterion : 1 . Disease progress treatment within 12 month completion adjuvant therapy tamoxifen and/or aromatase inhibitor ( AI ) . 2 . Disease progress treatment within 1 month end treatment prior tamoxifen , AI , cyclindependent kinase ( CDK ) 4/6 inhibitor plus letrozole , advanced/metastatic disease . Documentation ERpositive and/or progesterone receptor ( PR ) positive tumor . Documentation human epidermal growth factor receptor 2 ( HER2 ) negative tumor . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Adequate organ function per predefined hematologic , hepatic , renal , cardiac criterion . Prior therapy one line cytotoxic chemotherapy follow diagnosis advanced/metastatic disease , disease progress despite prior fulvestrant therapy . Concomitant active malignancy ER+ breast cancer . Therapeuticdose anticoagulation must discontinue coagulation parameter must normalize prior first dose GSK525762 fulvestrant . Evidence severe uncontrolled systemic disease ( example , unstable uncompensated respiratory , hepatic , renal , cardiac disease , clinically significant bleed episode ) . Subjects advanced/metastatic , symptomatic , visceral spread , risk lifethreatening complication short term include subject massive uncontrolled effusion , pulmonary lymphangitis , 50 % liver involvement metastasis . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . Cardiac abnormality</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GSK525762</keyword>
	<keyword>ER+ breast cancer</keyword>
	<keyword>mTPI</keyword>
</DOC>